Compare Biogen Inc (BIIB) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Waste Management, Inc. — how do they compare? Biogen Inc trades at $207.91 (market cap $30.13B), while Waste Management, Inc. trades at $227 (market cap $90.68B). The key difference: Waste Management, Inc. is far larger — about 3× Biogen Inc's market cap, and Waste Management, Inc. pays a 1.56% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | WM | |
|---|---|---|
Market Cap | $30.13B | $90.68B |
Sector | Health | Industrials |
52-Week High | $216.63 | $246.51 |
52-Week Low | $128.93 | $196.77 |
Enterprise Value | $37.20B | $113.47B |
Dividend Yield | — | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
WM trades at $227.2, up 0.26% on the day, with a neutral technical signal and strong analyst support. The company reported Q2 2026 EPS of $2.02, beating estimates, and maintains robust profitability with a net income margin of 11.12%. Revenue growth is steady, reaching $25.20B in 2025, though valuation multiples like a P/E of 59.74 appear elevated. Recent news highlights institutional trading activity and earnings focus on pricing discipline.
The outlook is positive with a consensus price target of $263.43, implying 16% upside, supported by 57% buy ratings. Risks include high debt levels and sensitivity to economic cycles, but consistent cash flow generation and margin gains provide a solid foundation for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
